Professor Jiong Shi graduated from Shanghai Medical University, and is MD, Ph.D., Chief physician and professor of Neurology of the Barrow Neurological Institute in Arizona, USA. He is the professor at the Department of Clinical Neuroscience at University of Arizona. He dedicated in medical research for more than 20 years, mainly engaged in molecular neurobiological mechanisms for neurodegenerative diseases, and conducted preclinical and early intervention interdisciplinary major project organizations and research at the level of gene, protein, cell, animal and clinical. He has presided over more than 40 clinical trials, including key clinical trials, which promoted the development and marketing of Exelon, Aricept, TYSABRI, Gilenya, Nuedexta and florbetapir for the benefit of patients. In translational studies, he sought a new biomarker for the early diagnosis of Alzheimer's disease and conducted preclinical work in treatment. His laboratory had collected evidence from a prospective study and obtained a patent for it. He has published 61 SCI articles in New England Journal of Medicine, JAMA Neurology, Neurology, Stroke, J Cereb Blood Flow Metab, etc. He served as the judge of SCI journals and various fund projects such as Annals of Neurology, Neurology, Journal of Nuclear Medicine, Frontiers in Cellular Neuroscience, Journal of Neuroinflammation, etc. He is a designated member of the Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment (ISTAART), Behavioral Neurology Section and Geriatric Neurology Section of American Academy of Neurology. He was nominated as “Best Doctors in America” , “Top Neurologist in Phoenix, AZ, the International Association of HealthCare Professionals” ,“America’s top physician, Consumers’ Research Council of America”, “Outstanding People of the 20th Century, International Biographical Center, Cambridge, England”. He is in charge of one global clinical trial “Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer’s Disease(AD)” in China this year.